About Annexon
Annexon is a company based in San Francisco (United States) founded in 2011.. Annexon has raised $256 million across 6 funding rounds from investors including Blackstone, BlackRock and Bain Capital. The company has 100 employees as of December 31, 2024. Annexon offers products and services including ANX005, ANX007, and ANX1502. Annexon operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Syndax and Horizon Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 100 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Annexon, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-138.2 M-2.95as on Dec 31, 2024
-
EBITDA
$-150.62 M-7.24as on Dec 31, 2024
-
Total Equity Funding
$256 M (USD)
in 6 rounds
-
Latest Funding Round
$130.48 M (USD), Post-IPO
Jul 08, 2022
-
Investors
Blackstone
& 17 more
-
Employee Count
100
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Annexon
Annexon is a publicly listed company on the NASDAQ with ticker symbol ANNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Annexon
Annexon offers a comprehensive portfolio of products and services, including ANX005, ANX007, and ANX1502. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody for treating Guillain-Barré syndrome by inhibiting C1q.
Inhibitor for eye diseases via intravitreal administration.
Targets C1q for autoimmune diseases in clinical trials.
Unlock access to complete
Unlock access to complete
Leadership Team
33 people
Operations Team
8 people
Scientific Team
6 people
Board Team
5 people
Software Development Team
4 people
Product Management Team
4 people
Finance and Accounting
3 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Annexon
Annexon has successfully raised a total of $256M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130.48 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $130.5M
-
First Round
First Round
(19 Aug 2011)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Post-IPO - Annexon | Valuation |
investors |
|
| Jul, 2020 | Amount | Series D - Annexon | Valuation | Redmile Group | |
| Dec, 2018 | Amount | Series C - Annexon | Valuation | Bain Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Annexon
Annexon has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, BlackRock and Bain Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Annexon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Annexon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Annexon Comparisons
Competitors of Annexon
Annexon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Syndax and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Annexon
Frequently Asked Questions about Annexon
When was Annexon founded?
Annexon was founded in 2011.
Where is Annexon located?
Annexon is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Annexon a funded company?
Annexon is a funded company, having raised a total of $256M across 6 funding rounds to date. The company's 1st funding round was a Series C of $75M, raised on Aug 19, 2011.
How many employees does Annexon have?
As of Dec 31, 2024, the latest employee count at Annexon is 100.
What does Annexon do?
Developer of antibodies to treat complement-mediated neurodegenerative diseases. The company is developing the antibody pipeline is based on research involving the classical complement pathway and the role of its initiating molecule, C1q, in the loss of nerve connections and inflammation. It claims to focus on treating diseases such as Alzheimers disease, Huntingtons disease, and other neurodegenerative disorders.
Who are the top competitors of Annexon?
What products or services does Annexon offer?
Annexon offers ANX005, ANX007, and ANX1502.
Is Annexon publicly traded?
Yes, Annexon is publicly traded on NASDAQ under the ticker symbol ANNX.
Who are Annexon's investors?
Annexon has 18 investors. Key investors include Blackstone, BlackRock, Bain Capital, Citadel, and Janus Henderson Investors.
What is Annexon's ticker symbol?
The ticker symbol of Annexon is ANNX on NASDAQ.